Status:
COMPLETED
Natural Killer Index From Hematopoietic Stem Cell Graft
Lead Sponsor:
Nantes University Hospital
Conditions:
Acute Lymphoblastic Leukemia
Acute Myeloblastic Leukemia
Eligibility:
All Genders
1+ years
Phase:
NA
Brief Summary
Numerous studies about the potential role of NK alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the KIR receptors and on genotypic incompatibilities between...
Eligibility Criteria
Inclusion
- Age superior to 1 year
- Patient that will be treated by an HSC graft
- Initial pathology of recipient: acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myeloid leukemia
Exclusion
- Patient already included in a study with an exclusion period
- HIV + or HCV + serology during pre-graft analysis
- Patient already treated by an allograft of HSC
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00435864
Start Date
April 1 2007
End Date
November 1 2013
Last Update
April 30 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nantes
Nantes, France, 44093